Article
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Gastroenterology - 1 Nov 2016
Lawitz Eric, Reau Nancy, Hinestrosa Federico, Rabinovitz Mordechai, Schiff Eugene, Sheikh Aasim, Younes Ziad, Herring Robert, Reddy K Rajender, Tran Tram, Bennett Michael, Nahass Ronald, Yang Jenny C, Lu Sophia, Dvory-Sobol Hadas, Stamm Luisa M, Brainard Diana M, McHutchison John G, Pearlman Brian, Shiffman Mitchell, Hawkins Trevor, Curry Michael, Jacobson Ira
Abstract excerpt
BACKGROUND & AIMS: The best regimen to re-treat patients who do not respond to direct-acting antivirals (DAAs) and the feasibility of further shortening regimens is unclear. We assessed the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in patients with hepatitis C virus genotype 1 infection....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.